EU/3/10/745: Orphan designation for the treatment of multiple myeloma


Table of contents


Please note that this product (marketed as Neofordex) was withdrawn from the Community Register of designated orphan medicinal products in January 2016 at the request of the sponsor, at the time of the granting of a marketing authorisation.

On 9 June 2010, orphan designation (EU/3/10/745) was granted by the European Commission to Laboratoires C.T.R.S., France, for dexamethasone (40 mg tablet) for the treatment of multiple myeloma.

Key facts

Active substance
Medicine name
Intended use
Treatment of multiple myeloma
Orphan designation status
EU designation number
Date of designation
Laboratoires CTRS (Cell Therapies Research & Services)
63 rue de l’Est
92100 Boulogne Billancourt
Tel. +33 1412 20970
Fax +33 1412 20236

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating